This company listing is no longer active
4OD Stock Overview
A pharmaceutical company, develops therapeutics for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Odonate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.23 |
| 52 Week High | US$2.90 |
| 52 Week Low | US$0.88 |
| Beta | 0.062 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -55.44% |
| 3 Year Change | -95.57% |
| 5 Year Change | n/a |
| Change since IPO | -93.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4OD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | 1.2% |
| 1Y | -55.4% | -27.8% | 14.0% |
Return vs Industry: 4OD underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 4OD underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 4OD volatility | |
|---|---|
| 4OD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4OD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4OD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 145 | Kevin Tang | www.odonate.com |
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Odonate Therapeutics, Inc. Fundamentals Summary
| 4OD fundamental statistics | |
|---|---|
| Market cap | €43.79m |
| Earnings (TTM) | -€101.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 4OD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4OD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$102.07m |
| Earnings | -US$102.07m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4OD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/08 15:37 |
| End of Day Share Price | 2022/08/11 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Odonate, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dana Flanders | Goldman Sachs |
| Michael Yee | Jefferies LLC |
| Eric Schmidt | TD Cowen |